Sfoglia per AUTORE
ZAGONEL V
Collezione AOU San Luigi di Orbassano

  

Items : 10

Synaptophysin expression in (V600EBRAF-)mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Mar;146:145-154. doi: 10.1016/j.ejca.2021.01.016. Epub 2021 Feb 16.

2021
AOU San Luigi di Orbassano
AO Ordine Mauriziano

Dei Tos AP; Lonardi S; Zagonel V; Borga C; Biason P; Centonze G; Santini D; Salmaso R; Aprile G; Salvatore L; Calvetti L; Smiroldo V; Rimassa L; De Maglio G; Cortiula F; Morano F; Volante M; Boccaccino A; Bergamo F; Zichi C; Sperti E; Dell'Aquila E; Pella N; Pietrantonio F; Schirripa M; Cremolini C; Maddalena G; Milione M; Fassan M; et alii...

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. in Liver cancer / Liver Cancer. 2021 Jul;10(4):370-379. doi: 10.1159/000515551. Epub 2021 Jun 15.

2021
AOU San Luigi di Orbassano

Tovoli F; Dadduzio V; De Lorenzo S; Rimassa L; Masi G; Iavarone M; Marra F; Garajova I; Brizzi MP; Daniele B; Trevisani F; Messina C; Di Clemente F; Pini S; Cabibbo G; Granito A; Rizzato MD; Zagonel V; Brandi G; Pressiani T; Federico P; Vivaldi C; Bergna I; Campani C; Piscaglia F;

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.

2020
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli

Buttigliero C; Zucali P; Tucci M; Verri E; Mosca A; Procopio G; Mucciarini C; Fratino L; Masini C; Massari F; Fornarini G; Ermacora P; Donini M; Buti S; Ceresoli GL; Berruti A; Caffo O; Bortolus R; Baldessari C; Zagonel V;

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2020 Feb;18(1):69-76.e4. doi: 10.1016/j.clgc.2019.09.010. Epub 2019 Sep 27.

2020
AOU San Luigi di Orbassano

Pappagallo G; Galli L; Gelderblom H; Tucci M; De Giorgi U; Zagonel V; Sella A; Bournakis E; Yu EY; Schmid S; Thomsen FB; Bergman A; Bianchini D; Wissing M; Caffo O; Bria E; Sperduti I; Oudard S;

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. in JAMA oncology / JAMA Oncol. 2019 Sep 1;5(9):1268-1275. doi: 10.1001/jamaoncol.2019.1467.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Longarini R; Petrelli F; Giordano M; Tomasello G; Adamo V; Zaniboni A; Murialdo R; Smiroldo V; Niger M; Antista M; Caporale M; Berenato R; Clavarezza M; Racca P; Tampellini M; Sartore-Bianchi A; Bergamo F; Rimassa L; Cremolini C; Raimondi A; Lonardi S; Miceli R; Corallo S; Pietrantonio F; Morano F; Cinieri S; Falcone A; Zagonel V; Di Bartolomeo M; et alii...

Metastatic castration-resistant prostate cancer (MCRPC) patients long term responders (LTR) to the a new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA in Anticancer Research

2017
AOU San Luigi di Orbassano

Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Facchini G; Iacovelli R; Mucciarini C; Zucali PA; Vicario G; Carrozza F; Sirotova Z; Messina C; Bordonaro R; La Torre L; Sacco C; Veccia A; Sperduti I; Zagonel V;

Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA in Journal of Clinical Oncology

2017
AOU San Luigi di Orbassano

Caffo O; Bria E; De Giorgi U; Tucci M; Biasco E; Fratino L; Rossetti S; Iacovelli R; Morelli F; D'Angelo A; Campadelli E; Verderame F; Borsellino N; Sartori D; Guida A; Ricotta R; Barni S; Maines F; Sperduti I; Zagonel V;

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.

2016
AOU San Luigi di Orbassano
ASL Torino 5

Santini D; Messina C; Perin A; Lodde M; Fratino L; Berruti A; Mucciarini C; Nicodemo M; Bonetti A; Alesini D; Zucali PA; Vicario G; Massari F; Lo Re G; Donini M; Bortolus R; Spizzo G; D'Angelo A; Zagonel V; Procopio G; Mattioli R; Mansueto G; Facchini G; Aieta M; Scognamiglio F; Ortega C; Di Lorenzo G; Caffo O; De Giorgi U; et alii...

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study in Journal of Clinical Oncology

2016
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Alesini D; Fratino L; Ortega C; Tucci M; Scagliarini S; Zagonel V; Zucali PA; Morelli F; Sartori D; Sabbatini R; D'Angelo A; Donini M; Barni S; Procopio G; Sirotova Z; Sava T; Conteduca V; Galligioni E;

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. in European urology / Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25.

2015
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; et alii...